ResearcherUniversity of UtahActive in the last 2 years

Zach Rubnitz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-7370-4075; OpenAlex author ID A5093395779. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2025: 2 papers

Papers 2

KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamanetworkopen.2024.53588 ↗
Gemcitabine-induced myositis in a patient with pancreatic cancer. Co-author DOI 10.1136/bcr-2024-259660 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chris Nevala-Plagemann · 2 shared papers, 2025 · strength 0.63
- Paper Gemcitabine-induced myositis in a patient with pancreatic cancer. DOI 10.1136/bcr-2024-259660 ↗
- Paper KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1001/jamanetworkopen.2024.53588 ↗
Ignacio Garrido‐Laguna · 2 shared papers, 2025 · strength 0.63
- Paper Gemcitabine-induced myositis in a patient with pancreatic cancer. DOI 10.1136/bcr-2024-259660 ↗
- Paper KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1001/jamanetworkopen.2024.53588 ↗
Vaia Florou · 2 shared papers, 2025 · strength 0.63
- Paper Gemcitabine-induced myositis in a patient with pancreatic cancer. DOI 10.1136/bcr-2024-259660 ↗
- Paper KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1001/jamanetworkopen.2024.53588 ↗
Heloisa Prado Soares · 1 shared paper, 2025 · strength 0.27
- Paper KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1001/jamanetworkopen.2024.53588 ↗
Carter Norton · 1 shared paper, 2025 · strength 0.27
- Paper KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1001/jamanetworkopen.2024.53588 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.